Compare CBU & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBU | DYN |
|---|---|---|
| Founded | 1866 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.4B |
| IPO Year | N/A | 2020 |
| Metric | CBU | DYN |
|---|---|---|
| Price | $62.47 | $17.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 17 |
| Target Price | ★ $64.00 | $39.94 |
| AVG Volume (30 Days) | 245.2K | ★ 2.2M |
| Earning Date | 01-27-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 15.41 | N/A |
| EPS | ★ 3.97 | N/A |
| Revenue | ★ $796,942,000.00 | N/A |
| Revenue This Year | $12.96 | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | $15.74 | ★ N/A |
| Revenue Growth | ★ 10.15 | N/A |
| 52 Week Low | $49.44 | $6.36 |
| 52 Week High | $68.11 | $25.00 |
| Indicator | CBU | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 45.63 |
| Support Level | $59.61 | $17.28 |
| Resistance Level | $63.00 | $18.58 |
| Average True Range (ATR) | 1.62 | 0.85 |
| MACD | -0.06 | 0.11 |
| Stochastic Oscillator | 49.56 | 65.89 |
Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional and governmental customers. The Company also offers comprehensive financial planning, trust administration and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services and Wealth Management Services.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.